Rna Diagnostics
Founded 2010 · 12 employees on LinkedIn · 2 known investors
RNA Diagnostics is a clinical-stage molecular diagnostics company whose Veridapt DX predictive biomarker platform measures early tumor response to neoadjuvant cancer therapy by monitoring RNA (rRNA) disruption in cells. The test helps physicians decide whether to escalate, de-escalate, or change treatment as early as five weeks into a regimen, with an initial focus on primary breast cancer but applicability to any solid tumor.
Investors · 2
Frequently asked questions
- What does Rna Diagnostics do?
- RNA Diagnostics is a clinical-stage molecular diagnostics company whose Veridapt DX predictive biomarker platform measures early tumor response to neoadjuvant cancer therapy by monitoring RNA (rRNA) disruption in cells. The test helps physicians decide whether to escalate, de-escalate, or change treatment as early as five weeks into a regimen, with an initial focus on primary breast cancer but applicability to any solid tumor.
- Who are Rna Diagnostics's investors?
- Rna Diagnostics's investors include Georgian Angel Network, iGan Partners.